Loading...

John Park, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address2340 Sutter Street
San Francisco CA 94115
Phone415-502-4158
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine

    Collapse Overview 
    Collapse Overview
    John W. Park, MD, is Professor of Medicine in the Division of Hematology/Oncology at University of California, San Francisco (UCSF) School of Medicine, and Director of Novel Therapeutics in Breast Oncology at the UCSF Comprehensive Cancer Center. Dr. Park received his AB degree at Harvard College, and MD degree at Stanford University School of Medicine. Dr. Park completed his residency training in Internal Medicine at UCLA Medical Center, and fellowship training in Hematology/Oncology at UCSF Medical Center. Dr. Park was also a visiting scientist at Genentech, Inc., where he worked on the development of trastuzumab (HerceptinTM).

    Dr. Park has been the recipient of multiple honors and awards, including the ASCO Young Investigator Award, the Career Development Award from the US Department of Defense Breast Cancer Research Program, and Top Doctor from US News & World Report. Dr. Park has authored over 130 published papers and authored or edited 18 books/book chapters on cancer research. Dr. Park is also an inventor with multiple US patents relating to new cancer treatments.

    Dr. Park’s major research interests include novel targeted cancer therapeutics and new cancer biomarkers. Dr. Park’s research is well known for its discovery and development of targeted therapeutics using nanoparticle/liposome/immunoliposome technologies. These include nanoliposomal irinotecan (nal-IRI, OnivydeTM), which received US FDA approval in 2015, as well as novel immunoliposome drugs. Dr. Park is also a noted expert in the field of circulating tumor cell and biomarker studies.

    Collapse Research 
    Collapse Research Activities and Funding
    Brain Tumor SPORE Grant
    NIH/NCI P50CA097257Sep 20, 2002 - Aug 31, 2023
    Role: Co-Investigator
    Mechanism-Based Evaluations of ErbB-Targeted Agents
    NIH/NCI U54CA090788Sep 26, 2001 - Dec 31, 2008
    Role: Co-Investigator
    ANTIERBB2 ANTIBODY INDUCED PROTEIN INTERACTIONS
    NIH/FIC R03TW000871Jul 1, 1999 - May 31, 2004
    Role: Principal Investigator
    SPORE in Breast Cancer
    NIH/NCI P50CA058207Aug 1, 1997 - Sep 29, 1995
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab. Clin Cancer Res. 2020 Jun 25. Magbanua MJM, Savenkov O, Asmus EJ, Ballman K, Scott JH, Park JW, Dickler M, Partridge AH, Carey LA, Winer E, Rugo HS. PMID: 32586939.
      View in: PubMed   Mentions:    Fields:    
    2. Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. Breast Cancer Res Treat. 2019 Sep; 177(2):401-408. Melisko ME, Assefa M, Hwang J, DeLuca A, Park JW, Rugo HS. PMID: 31172405.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer. Clin Cancer Res. 2019 09 01; 25(17):5388-5397. Magbanua MJM, Yau C, Wolf DM, Lee JS, Chattopadhyay A, Scott JH, Bowlby-Yoder E, Hwang ES, Alvarado M, Ewing CA, Delson AL, Van't Veer LJ, Esserman L, Park JW. PMID: 31142502.
      View in: PubMed   Mentions:    Fields:    
    4. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ Breast Cancer. 2018; 4:31. Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW. PMID: 30211312.
      View in: PubMed   Mentions:
    5. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst. 2018 06 01; 110(6):560-567. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K. PMID: 29659933.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    6. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clin Cancer Res. 2018 03 15; 24(6):1486-1499. Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, Hyslop T, Barry WT, Isakoff SJ, Dickler M, Van't Veer L, Park JW. PMID: 29311117.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    7. Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel. 2018 01 01; 31(1):17-28. Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD. PMID: 29301020.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    8. Pure CTCs, advanced WGS, and precise personalized combination therapies. Oncoscience. 2017 Jul; 4(7-8):75-76. Peters BA, Park JW, Drmanac R. PMID: 28966939.
      View in: PubMed   Mentions:
    9. Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. Cancer Res. 2017 08 15; 77(16):4530-4541. Gulbahce N, Magbanua MJM, Chin R, Agarwal MR, Luo X, Liu J, Hayden DM, Mao Q, Ciotlos S, Li Z, Chen Y, Chen X, Li Y, Zhang RY, Lee K, Tearle R, Park E, Drmanac S, Rugo HS, Park JW, Drmanac R, Peters BA. PMID: 28811315.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    10. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017 Mar 01; 3(3):313-319. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS. PMID: 27832260.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    11. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol. 2017 03; 79(3):603-610. Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. PMID: 28233053.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    12. Enumeration of Circulating Tumor Cells and Disseminated Tumor Cells in Blood and Bone Marrow by Immunomagnetic Enrichment and Flow Cytometry (IE/FC). Methods Mol Biol. 2017; 1634:203-210. Magbanua MJM, Solanki TI, Ordonez AD, Hsiao F, Park JW. PMID: 28819853.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    13. Enrichment and Detection of Circulating Tumor Cells and Other Rare Cell Populations by Microfluidic Filtration. Adv Exp Med Biol. 2017; 994:119-131. Pugia M, Magbanua MJM, Park JW. PMID: 28560671.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    14. Automated Microfluidic Filtration and Immunocytochemistry Detection System for Capture and Enumeration of Circulating Tumor Cells and Other Rare Cell Populations in Blood. Methods Mol Biol. 2017; 1634:119-131. Pugia M, Magbanua MJM, Park JW. PMID: 28819845.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    15. Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat. 2016 12; 160(3):411-424. Lee JS, Magbanua MJM, Park JW. PMID: 27761678.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    16. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. PMID: 27406346.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    17. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015 Nov; 154(2):339-49. Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW. PMID: 26520840.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    18. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One. 2015; 10(10):e0141166. Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A, Rugo HS, Park JW. PMID: 26496203.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    19. Approaches to isolation and molecular characterization of disseminated tumor cells. Oncotarget. 2015 Oct 13; 6(31):30715-29. Magbanua MJ, Das R, Polavarapu P, Park JW. PMID: 26378808.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    20. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015 May 29; 17:73. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, Esserman L, Park JW, van 't Veer LJ. PMID: 26021444.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    21. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015 Mar 31; 15:206. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. PMID: 25884197.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsCTClinical Trials
    22. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. PMID: 25712686.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    23. Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res. 2015 Mar 01; 21(5):1098-105. Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS. PMID: 25524311.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    24. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. PMID: 25432738.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    25. Advances in genomic characterization of circulating tumor cells. Cancer Metastasis Rev. 2014 Sep; 33(2-3):757-69. Magbanua MJ, Park JW. PMID: 24867683.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    26. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature. 2014 Jul 17; 511(7509):319-25. Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM. PMID: 25030168.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansAnimalsCells
    27. Genome-wide copy number analysis of cerebrospinal fluid tumor cells and their corresponding archival primary tumors. Genom Data. 2014 Dec; 2:60-2. Magbanua MJ, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Melisko M, Park JW. PMID: 26484071.
      View in: PubMed   Mentions:
    28. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. PMID: 24711549.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    29. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res. 2013 Dec 01; 73(23):7134-43. Magbanua MJ, Melisko M, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Park JW. PMID: 24142343.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    30. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. PMID: 24022191.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    31. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Methods. 2013 Dec 01; 64(2):114-8. Magbanua MJ, Park JW. PMID: 23896286.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    32. Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. Nanomedicine (Lond). 2013 Dec; 8(12):1913-25. Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW. PMID: 23631502.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    33. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. PMID: 23470967.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    34. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res. 2013 Jan 01; 73(1):30-40. Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW. PMID: 23135909.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    35. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat. 2012 Oct; 135(3):913-22. Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, Van't Veer L, Esserman LJ. PMID: 22941572.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    36. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer. 2012 Feb 28; 12:78. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW. PMID: 22373240.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    37. Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles. J Nucl Med. 2012 Mar; 53(3):480-7. Gedda L, Fondell A, Lundqvist H, Park JW, Edwards K. PMID: 22323773.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    38. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(1):13-20. Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. PMID: 22198412.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    39. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2724-9. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT. PMID: 22003129.
      View in: PubMed   Mentions: 188     Fields:    Translation:HumansCells
    40. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat. 2011 Sep; 129(2):607-16. Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. PMID: 21597921.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    41. Disseminated tumor cells: the method is the message. Breast Cancer Res Treat. 2011 Feb; 125(3):739-40. Park JW. PMID: 20700647.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    42. Characterization of a novel, trastuzumab resistant human breast cancer cell line. Front Biosci (Elite Ed). 2010 Jan 01; 2:627-40. Barok M, Balazs M, Lazar V, Rakosy Z, Toth E, Treszl A, Vereb G, Colbern GT, Park JW, Szollosi J. PMID: 20036907.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    43. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol. 2010 Feb 01; 28(4):628-33. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA, Dickler MN. PMID: 19841327.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    44. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res. 2009 Sep 15; 15(18):5937-44. Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW. PMID: 19723649.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    45. A comparison of RNA amplification techniques at sub-nanogram input concentration. BMC Genomics. 2009 Jul 20; 10:326. Lang JE, Magbanua MJ, Scott JH, Makrigiorgos GM, Wang G, Federman S, Esserman LJ, Park JW, Haqq CM. PMID: 19619282.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    46. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7878-83. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. PMID: 19047117.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    47. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer. 2008 Oct; 8(5):392-401. Park JW, Neve RM, Szollosi J, Benz CC. PMID: 18952552.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    48. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 2008 Sep; 8(9):2851-7. Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Chen FF, Drummond DC, Kirpotin DB, Wang D, Hom YK, Hann B, Park JW. PMID: 18712930.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    49. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett. 2008 Feb 18; 260(1-2):198-208. Barok M, Balázs M, Nagy P, Rákosy Z, Treszl A, Tóth E, Juhász I, Park JW, Isola J, Vereb G, Szöllosi J. PMID: 18096313.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    50. A role for biomarkers in the screening and diagnosis of breast cancer in younger women. Expert Rev Mol Diagn. 2007 Sep; 7(5):533-44. Esserman LJ, Shieh Y, Park JW, Ozanne EM. PMID: 17892362.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    51. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20; 25(24):3680-7. Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. PMID: 17704416.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    52. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol. 2007 Oct; 9(4):393-403. Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, Kullberg E, Forsayeth J, Park JW, Bankiewicz KS. PMID: 17652269.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    53. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol. 2007 Jun; 71(6):1525-34. Marx C, Yau C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, Benz CC. PMID: 17392524.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    54. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int. 2007 Mar; 99(3):519-24. Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ. PMID: 17407512.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    55. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 2007 Apr; 25(3):319-27. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM. PMID: 17371720.
      View in: PubMed   Mentions: 39     Fields:    Translation:Animals
    56. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol. 2007 Jan; 9(1):20-8. Yamashita Y, Krauze MT, Kawaguchi T, Noble CO, Drummond DC, Park JW, Bankiewicz KS. PMID: 17018695.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    57. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol. 2006 Jul; 8(3):205-14. Saito R, Krauze MT, Noble CO, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS. PMID: 16723630.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    58. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 2006 Mar 01; 66(5):2801-6. Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW. PMID: 16510602.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    59. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005 Dec 15; 65(24):11631-8. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. PMID: 16357174.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCells
    60. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol. 2005 Dec; 196(2):381-9. Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Hong K, Berger MS, Park JW, Bankiewicz KS. PMID: 16197944.
      View in: PubMed   Mentions: 61     Fields:    Translation:Animals
    61. Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc. 2005 Dec; 16(1-3):20-6. Krauze MT, Mcknight TR, Yamashita Y, Bringas J, Noble CO, Saito R, Geletneky K, Forsayeth J, Berger MS, Jackson P, Park JW, Bankiewicz KS. PMID: 16181805.
      View in: PubMed   Mentions: 45     Fields:    Translation:Animals
    62. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol. 2005 Aug 20; 23(24):5464-73. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. PMID: 16027440.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    63. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005 Aug 20; 23(24):5474-83. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. PMID: 16027439.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansCTClinical Trials
    64. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat. 2005 May; 91(2):163-71. Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ. PMID: 15868444.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    65. Brain metastases of breast cancer. Expert Rev Anticancer Ther. 2005 Apr; 5(2):253-68. Melisko ME, Kunwar S, Prados M, Berger MS, Park JW. PMID: 15877523.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    66. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol. 2004 Dec; 31(6 Suppl 13):196-205. Park JW, Benz CC, Martin FJ. PMID: 15717745.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    67. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets. 2004 Aug; 8(4):335-53. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. PMID: 15268628.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimals
    68. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer. 2004 Jul 01; 101(1):90-5. Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ. PMID: 15221993.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    69. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res. 2004 Jun 01; 10(11):3881-4. Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF. PMID: 15173097.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    70. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res. 2004 Jun 01; 10(11):3885-96. Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ. PMID: 15173098.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimals
    71. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol. 2004 May; 68(1):1-9. Mamot C, Nguyen JB, Pourdehnad M, Hadaczek P, Saito R, Bringas JR, Drummond DC, Hong K, Kirpotin DB, McKnight T, Berger MS, Park JW, Bankiewicz KS. PMID: 15174514.
      View in: PubMed   Mentions: 48     Fields:    Translation:Animals
    72. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 2004 Apr 01; 64(7):2572-9. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS. PMID: 15059914.
      View in: PubMed   Mentions: 81     Fields:    Translation:Animals
    73. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat. 2003 Oct; 6(5):271-9. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. PMID: 14643297.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    74. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003 Jun 15; 63(12):3154-61. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. PMID: 12810643.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    75. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002; 4(3):95-9. Park JW. PMID: 12052251.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    76. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002 Apr; 8(4):1172-81. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. PMID: 11948130.
      View in: PubMed   Mentions: 121     Fields:    Translation:HumansAnimalsCells
    John's Networks
    Concepts (311)
    Derived automatically from this person's publications.
    _
    Co-Authors (70)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _